These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35841237)

  • 1. Editorial: The dawn of a new era of Alzheimer's research and drug development.
    Hara Y; Fillit HM
    J Prev Alzheimers Dis; 2022; 9(3):385-386. PubMed ID: 35841237
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: Alzheimer's Disease Drug Development Pipeline 2020.
    Sabbagh MN
    J Prev Alzheimers Dis; 2020; 7(2):66-67. PubMed ID: 32236392
    [No Abstract]   [Full Text] [Related]  

  • 3. Future prospects and challenges for Alzheimer's disease drug development in the era of the NIA-AA Research Framework.
    Khachaturian AS; Hayden KM; Mielke MM; Tang Y; Lutz MW; Gustafson DR; Kukull WA; Mohs R; Khachaturian ZS
    Alzheimers Dement; 2018 Apr; 14(4):532-534. PubMed ID: 29653605
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial: Multi Target - Directed Ligands in the Treatment of Alzheimer's Disease.
    Soukup O; Korabecny J
    Curr Alzheimer Res; 2019; 16(9):771. PubMed ID: 31729288
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial: Next-Generation Alzheimer's Therapeutics: Leveraging Deep Biology.
    Longo FM; Massa SM
    J Prev Alzheimers Dis; 2020; 7(3):138-139. PubMed ID: 32463062
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial: The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) - A Fundamental Ally in AD Prevention Research.
    Porsteinsson AP; Clark ED
    J Prev Alzheimers Dis; 2020; 7(4):206-207. PubMed ID: 32920620
    [No Abstract]   [Full Text] [Related]  

  • 7. Commentary: Treating Alzheimer's Disease : Combine or Fail ?
    Bakchine S
    J Prev Alzheimers Dis; 2019; 6(3):174-176. PubMed ID: 31062828
    [No Abstract]   [Full Text] [Related]  

  • 8. New Approaches to Develop Drug Treatment for Alzheimer's Disease: Targeting Calcium Dysregulation.
    Wei H
    Curr Alzheimer Res; 2020; 17(4):311-312. PubMed ID: 32623998
    [No Abstract]   [Full Text] [Related]  

  • 9. The Role of Clinical Trials in Preclinical Alzheimer's Disease Drug Development Programs.
    Cummings J
    J Prev Alzheimers Dis; 2020; 7(4):288-290. PubMed ID: 32920632
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial: Can Digital Technology Advance the Development of Treatments for Alzheimer's Disease?
    Mc Carthy M; Schueler P
    J Prev Alzheimers Dis; 2019; 6(4):217-220. PubMed ID: 31686090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Magnetic Resonance Imaging in Alzheimer' Disease Drug Development.
    Holiga S; Abdulkadir A; Klöppel S; Dukart J
    Methods Mol Biol; 2018; 1750():159-163. PubMed ID: 29512071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's disease: future drug development and the blood-brain barrier.
    Pardridge WM
    Expert Opin Investig Drugs; 2019 Jul; 28(7):569-572. PubMed ID: 31155971
    [No Abstract]   [Full Text] [Related]  

  • 13. New Hope for Alzheimer's Disease.
    Vellas B; Aisen P
    J Prev Alzheimers Dis; 2021; 8(3):238-239. PubMed ID: 34101778
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug Development for Alzheimer's Disease: Microglia Induced Neuroinflammation as a Target?
    Dong Y; Li X; Cheng J; Hou L
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30696107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease research: the future of BACE inhibitors.
    Burki T
    Lancet; 2018 Jun; 391(10139):2486. PubMed ID: 29976459
    [No Abstract]   [Full Text] [Related]  

  • 16. Will We Have a Drug for Alzheimer's Disease by 2030? The View From Pharma.
    Lovestone S; Manji HK
    Clin Pharmacol Ther; 2020 Jan; 107(1):79-81. PubMed ID: 31758815
    [No Abstract]   [Full Text] [Related]  

  • 17. Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data.
    Conrado DJ; Duvvuri S; Geerts H; Burton J; Biesdorf C; Ahamadi M; Macha S; Hather G; Francisco Morales J; Podichetty J; Nicholas T; Stephenson D; Trame M; Romero K; Corrigan B;
    Clin Pharmacol Ther; 2020 Apr; 107(4):796-805. PubMed ID: 31955409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer's disease.
    Camins A; Ettcheto M; Busquets O; Manzine PR; Castro-Torres RD; Beas-Zarate C; Verdaguer E; Sureda FX; Bulló M; Olloquequi J; Auladell C; Folch J
    Expert Opin Investig Drugs; 2019 Jan; 28(1):93-97. PubMed ID: 30480461
    [No Abstract]   [Full Text] [Related]  

  • 19. The Role of Biomarkers in Alzheimer's Disease Drug Development.
    Cummings J
    Adv Exp Med Biol; 2019; 1118():29-61. PubMed ID: 30747416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Setbacks and promises for drugs against Alzheimer's disease: As pharmaceutical companies are retreating from drug development for Alzheimer's, new approaches are being tested in academia and biotech companies.
    Rinaldi A
    EMBO Rep; 2018 Sep; 19(9):. PubMed ID: 30150324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.